News Releases

Date Title
11/20/2017 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
11/13/2017 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017
11/10/2017 Summary ToggleEnanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™
10/23/2017 Summary ToggleEnanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305
10/20/2017 Summary ToggleEnanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017
10/11/2017 Summary ToggleEnanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017
09/27/2017 Summary ToggleEnanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017
09/27/2017 Summary ToggleEnanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C
09/13/2017 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors
08/30/2017 Summary ToggleEnanta Pharmaceuticals to Present at Three Upcoming Investor Conferences